Literature DB >> 21790901

The mGluR5 antagonist MPEP elevates accumbal dopamine and glycine levels; interaction with strychnine-sensitive glycine receptors.

PeiPei Chau1, Bo Söderpalm, Mia Ericson.   

Abstract

Studies have indicated that the metabotropic glutamate receptor 5 (mGluR5) antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) decreases ethanol self-administration, and the same receptor type was also suggested to be involved in the mechanism of action of the anti-craving substance acamprosate. Our previous research suggested that glycine receptors (GlyRs) in the nucleus accumbens (nAc) play a major part in mediating the dopamine-elevating properties of ethanol and are highly involved in the ethanol intake-reducing effect of acamprosate. The aim of this study was to examine if modulation of nAc dopamine via mGluR5 antagonism or GlyR agonism is a linked or separated phenomena. The extracellular levels of dopamine as well as of the GlyR ligands, glycine, taurine and β-alanine were measured in the nAc by means of microdialysis after local perfusion of MPEP (100 or 500 µM) with or without pre-treatment with strychnine. MPEP increased dopamine levels, an effect that was blocked by pre-treatment with strychnine. In addition, the higher MPEP concentration increased glycine output, whereas no alterations of taurine or β-alanine were observed. These results indicate a relationship between the glutamatergic and glycinergic transmitter systems in regulating dopamine output, possibly via alteration of extracellular glycine levels. Taken together with our previous data demonstrating the importance of accumbal GlyRs both in ethanol-induced elevation of nAc dopamine and in ethanol consumption, it is plausible that the effects of MPEP treatment, on dopamine output and on ethanol intake, may be mediated via interaction with the same neuronal circuitry that previously has been demonstrated for ethanol, taurine and acamprosate.
© 2011 The Authors, Addiction Biology © 2011 Society for the Study of Addiction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21790901     DOI: 10.1111/j.1369-1600.2011.00343.x

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  4 in total

1.  Pharmacoproteomics Profile in Response to Acamprosate Treatment of an Alcoholism Animal Model.

Authors:  Caroline E Germany; Ashlie N Reker; David J Hinton; Alfredo Oliveros; Xinggui Shen; Lindsey G Andres-Beck; Katheryn M Wininger; Marjan Trutschl; Urska Cvek; Doo-Sup Choi; Hyung W Nam
Journal:  Proteomics       Date:  2018-04       Impact factor: 3.984

2.  Blockade of Glutamate Receptors within the Prelimbic Cortex Attenuate Concentration of Excitatory Amino Acids in the Morphine Self-administration in Rats.

Authors:  Fateme Aboutalebi; Hojjatallah Alaei; Shahrbanoo Oryan
Journal:  Adv Biomed Res       Date:  2018-08-29

Review 3.  Glycine Signaling in the Framework of Dopamine-Glutamate Interaction and Postsynaptic Density. Implications for Treatment-Resistant Schizophrenia.

Authors:  Andrea de Bartolomeis; Mirko Manchia; Federica Marmo; Licia Vellucci; Felice Iasevoli; Annarita Barone
Journal:  Front Psychiatry       Date:  2020-05-14       Impact factor: 4.157

4.  Ventral tegmental area dopamine and GABA neurons: Physiological properties and expression of mRNA for endocannabinoid biosynthetic elements.

Authors:  Collin B Merrill; Lindsey N Friend; Scott T Newton; Zachary H Hopkins; Jeffrey G Edwards
Journal:  Sci Rep       Date:  2015-11-10       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.